natgillin/translations-raw huggingface dataset:
Izogibajte se neposredni izpostavljenosti močni notranji svetlobi vključno z zobozdravstvenimi svetilkami, lučmi v operacijskih dvoranah, nezasenčenimi žarnicami v neposredni bližini ali neonskimi lučmi.
Avoid direct exposure to bright indoor lights, including dental lamps, operating room lamps, unshaded light bulbs at close proximity or neon lights.
Izogniti se je treba profilaktični uporabi kortikosteroidov, da bi zmanjšali nastanek strikture med zdravljenjem s PDT, ker se je izkazalo, da njegova uporaba ni zmanjšala in da lahko celo poslabša nastanek zoženja.
Prophylactic use of corticosteroids to reduce stricture formation should be avoided during PDT as its use has shown not to reduce, and may worsen, stricture formation.
Izpadanje las.
Hair loss.
Izpuščaj
Rash
izpuščaj, srbenje, nenormalen občutek za dotik,
Rashes, itching, abnormal touch sensation
Izpuščaj/ luščenje
Rash/ desquamation
Izpuščaj/ luščenje
Rash/desquamation
Izpuščaj/luščenje
Rash/desquamation
Izraz periferna nevropatija vključuje naslednje neželene učinke, o katerih so poročali: periferno senzorično nevropatijo, parestezijo, hipestezijo, periferno nevropatijo, polinevropatijo, nevrotoksičnost in disestezijo.
The term peripheral neuropathy includes the following reported adverse reactions: peripheral sensory neuropathy, paraesthesia, hypoaesthesia, peripheral neuropathy, polyneuropathy, neurotoxicity, and dysaesthesia.
Izrazi za očesno toksičnost, povezano z zdravljenjem, so bili razvrščeni, kot sledi.
Terms for treatment-related ocular toxicities have been combined as follows.
Izračunajte BSA na 2 decimalni mesti. a Izraženo z vsebnostjo tegafurja.
Calculate BSA to 2 decimal places. a Expressed as tegafur content.
Izračunajte odmerek in število potrebnih vial zdravila Pemetreksed Hospira.
Calculate the dose and the number of Pemetrexed Hospira vials needed.
Izračunani očistek kreatinina ≥ 30 ml/mina
Calculated creatinine clearance ≥30 ml/mina
Izračuni odmerkov zdravila Teysuno
Teysuno dose calculations
Izsledki teh analiz učinkovitosti so povzeti v spodnji preglednici:
The results of these analyses of efficacy are summarised in the table below.
Izsledki študij in vitro s človeškimi jetrnimi mikrosomi so pokazali, da za pemetreksed ne pričakujemo, da bi povzročil klinično pomembno zaviranje presnovnega očistka zdravil, ki se presnavljajo s CYP3A, CYP2D6, CYP2C9 in CYP1A2.
Results from in vitro studies with human liver microsomes indicated that pemetrexed would not be predicted to cause clinically significant inhibition of the metabolic clearance of drugs metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2.
Izvedena je bila farmakokinetična študija po enem odmerku zdravila Pravafenix pri teščih in neteščih bolnikih.
A pharmacokinetic study after a single dose administration of Pravafenix has been performed in fed and fasting condition.
Izvedena je bila vnaprej določena analiza, sestavljena iz podatkov 927 bolnikov iz 1. in 2. študije PsA.
A pre-specified integrated analysis combining data from 927 subjects in both PsA Study 1 and 2 was performed.
Izvedli so 18 dodatnih PK-študij, pri katerih je upoštevna shema zdravljenja pomenila samostojno zdravljenje.
Eighteen additional PK studies were performed using the relevant regimen as monotherapy.
izvidov krvnih preiskav, opravljenih pred začetkom zdravljenja in med zdravljenjem, od vašega prenašanja zdravila.
the results of blood tests carried out before and during treatment how well you tolerate treatment.
IΓαλλία
Γαλλία
J L Bragg Limited, 33-34 Boss Hall Road, Ipswich, Suffolk, IP1 5BN, Великобритания.
J L Bragg Limited, 33-34 Boss Hall Road, Ipswich, Suffolk, IP1 5BN, United Kingdom.
j напр. хематурия, хеморагичен цистит
j e.g. haematuria, cystitis haemorrhagic
J. Uriach y Compañía, S.A.
J. Uriach y Compañía, S.A. Av.
J.E. Mommaertslaan 14 BE–1831 Diegem (Machelen) Belgique/Belgien
J.E. Mommaertslaan 14 BE–1831 Diegem (Machelen)
Jak alli působí
How alli works
Jak alli uchovávat
How to store alli
Jak alli vypadá a co obsahuje toto balení
What alli looks like and contents of the pack
Jak dlouho se má alli užívat
How long should I take alli for?
Jak dlouho se má alli užívat?
How long should I take alli for?
Jak EVOTAZ uchovávat
How to store EVOTAZ
Jak EVOTAZ vypadá a co obsahuje toto balení
What EVOTAZ looks like and contents of the pack
Jak hlásit nežádoucí účinky je popsáno v závěru bodu 4.
See the end of section 4 for how to report side effects.
Jak kvůli potenciálu pro přenos HIV, tak kvůli potenciálu pro závažné nežádoucí účinky u kojených dětí mají být ženy poučeny, aby nekojily, pokud užívají přípravek EVOTAZ.
Because of both the potential for HIV transmission and the potential for serious adverse reactions in breast- feeding infants, women should be instructed not to breast-feed if they are receiving EVOTAZ.
Jak přípravek Intuniv uchovávat
How to store Intuniv
Jak přípravek Intuniv vypadá a co obsahuje toto balení
What Intuniv looks like and contents of the pack
Jak se alli užívá
How to take alli
JAK SE CLOPIDOGREL BMS UŽÍVÁ
HOW TO TAKE CLOPIDOGREL BMS
Jak se EVOTAZ užívá
How to take EVOTAZ
Jak se přípravek Intuniv užívá
How to take Intuniv
Jak užívat:
How to use
Jakavi 10 mg таблетки Руксолитиниб
Jakavi 10 mg tablets Ruxolitinib
Jakavi 15 mg таблетки Руксолитиниб
Jakavi 15 mg tablets Ruxolitinib
Jakavi 20 mg таблетки Руксолитиниб
Jakavi 20 mg tablets Ruxolitinib
Jakavi 5 mg таблетки Руксолитиниб
Jakavi 5 mg tablets Ruxolitinib
jako lék povzbuzující bdělost a k léčbě poruch spánku.
Is a medicine that promotes alertness and is used to treat sleep disorders.
Jakost
(Invented) name
Jakost
Name
Jakost
number
Jakost
Strength
Jakékoli příznaky zánětu mají být vyhodnoceny a v případě potřeby má být zahájena příslušná léčba.
Any inflammatory symptoms should be evaluated and treatment instituted when necessary.
Jalra 50 mg tablets вилдаглиптин
Jalra 50 mg tablets vildagliptin
Jalra 50 mg таблетки са овални, бели до бледо жълти и плоски таблетки с “NVR” от едната страна и “FB” от другата.
Jalra 50 mg tablets are round, white to light yellowish and flat, with “NVR” on one side and “FB” on the other.
Jalra vildagliptin
EMEA/H/C/001048
Jalra може да се прилага със или без храна (вж. също точка 5.2).
Jalra can be administered with or without a meal (see also section 5.2).
Jalra не трябва да се прилага при пациенти с чернодробно увреждане, включително пациенти със стойности на АЛАТ или АСАТ преди започване на лечението > 3 пъти ГГН (вж. също точки 4.2 и 5.2).
Jalra should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN (see also sections 4.2 and 5.2).
JAMA 204; 292(23): 2839-2848.
JAMA 2004; 292(23): 2839-2848.
JAMA 204;292(23):2839-2848.
JAMA 2004; 292(23): 2839-2848.
Jana Pawla II/15
Jana Pawła II nr 15
Janssen Biologics (Irska) Barnahely
Janssen Biologics (Ireland) Barnahely
Janssen Biologics B.V.
Posology
Janssen Biologics B.V., Einsteinweg 101 2333 CB Leiden, Нидерландия
Janssen Biologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands
Janssen Pharmaceutica N.V..
Janssen Pharmaceutica N.V.
Janssen Pharmaceutica NV Turnhoutseweg 30
Janssen Pharmaceutica N.V. Turnhoutseweg 30
Janssen Pharmaceutica NV Turnhoutseweg 30
Turnhoutseweg 30 Turnhoutseweg 30
Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Белгия
Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
JANSSEN-CILAG FARMACEUTICA, LDA Tel: +351 21-4368835
JANSSEN-CILAG FARMACEUTICA, LDA Tel: +351 21 4368835
JANSSEN-CILAG GmbH Tel: +49 2137-955-955
JANSSEN-CILAG GmbH Tel: +49 2137 955 955
Janssen-Cilag International N.V. Turnhoutseweg, 30
Janssen-Cilag International NV Turnhoutseweg, 30
Janssen-Cilag International NV Turnhoutseweg 30
Janssen-Cilag International NV
JANSSEN-CILAG INTERNATIONAL NV,
JANSSEN-CILAG INTERNATIONAL NV
Janssen-Cilag International NV, Turnhoutseweg 30,
Janssen-Cilag International NV Turnhoutseweg 30
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Белгия
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Janssen-Cilag Polska Sp.z o.o. filiāle Latvijā Tel: +371 678 93561
Janssen-Cilag Polska Sp. z o.o. filiāle Latvijā Tel: + 371 678 93561
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Италия
Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy
JANSSEN-CILAG Φαρμακευτική Α.Ε.Β.Ε. Τηλ: +30210 61 809 0000
JANSSEN-CILAG Φαρμακευτική Α.Ε.Β.Ε. Τηλ: +30 210 809 0000
Janssen-Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
Janssen-Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium.
Janumet 50 mg/1 000 mg филмирани таблетки ситаглиптин/метформинов хидрохлорид
Janumet 50 mg/1,000 mg film-coated tablets sitagliptin/metformin hydrochloride
Janumet 50 mg/850 mg филмирани таблетки ситаглиптин/метформинов хидрохлорид
Janumet 50 mg/850 mg film-coated tablets sitagliptin/metformin hydrochloride
Janumet e показан като тройно комбинирано лечение с пероксизомен пролифератор-активиран рецептор гама (PPAR) агонист (т.е. тиазолидиндион) като допълнение към диета и упражнения при пациенти, при които не е постигнат задоволителен контрол с максималната поносима за тях доза метформин и PPAR агонист.
Janumet is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
Janumet е лекарство, което съдържа две активни вещества – ситаглиптин (sitagliptin) и метформин хидрохлорид (metformin hydrochloride).
Janumet is a medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Janumet не трябва да се използва при пациенти с умерено или тежко бъбречно увреждане (креатининов клирънс < 60 ml/min) (вж. точки 4.3 и 4.4).
Janumet should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 mL/min) (see sections 4.3 and 4.4).
Janumet не трябва да се използва при пациенти с чернодробно увреждане (вж. точки 4.3 и 5.2).
Janumet must not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Janumet съдържа две различни лекарства, наречени ситаглиптин и метформин. ситаглиптин принадлежи към клас лекарства, наречени DPP-4 инхибитори (дипептидил пептидаза-4 инхибитори) метформин принадлежи към клас лекарства, наречени бигванидини.
Janumet contains two different medicines called sitagliptin and metformin. sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) metformin belongs to a class of medicines called biguanides.
Janumet също е показан като дoбавка към инсулин (т.е. тройно комбинирано лечение) като допълнение към диетата и упражненията за подобряване на гликемичния контрол при пациенти, когато постоянната доза на инсулин и метформин самостоятелно не осигурява адекватен гликемичен контрол.
Janumet is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Januvia е проучен в девет проучвания при почти 6000 пациенти с диабет тип 2, чиито нива на глюкоза в кръвта не са контролирани задоволително: четири от проучванията сравняват Januvia с плацебо (сляпо лечение).
Januvia was studied in nine studies involving almost 6,000 patients with type 2 diabetes whose blood glucose levels were not adequately controlled: four of the studies compared Januvia with placebo (a dummy treatment).
Januvia или плацебо са прилагани самостоятелно в две проучвания при 1262 пациенти, като допълнителна терапия към метформин в едно проучване при 701 пациенти и като допълнителна терапия към пиоглитазон (PPAR-гама агонист) в едно проучване при 353 пациенти; две проучвания сравняват Januvia с други противодиабетни лекарства.
Januvia or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients; two studies compared Januvia with other antidiabetes medicines.
Januvia може да се приема със или без храна.
Januvia can be taken with or without food.
Januvia съдържа активното вещество ситаглиптин, което е представител на клас лекарства, наричани ДПП-4 инхибитори (дипептидил пептидаза-4 инхибитори), които намаляват нивата на кръвната захар при пациенти със захарен диабет тип 2.
Januvia contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Jaotumine
Distribution
Jaotusruumala tasakaalukontsentratsiooni faasis (Vss) oli ligikaudu 18 – 19 liitrit.
The volume of distribution at steady state (Vss) was approximately 18-19 litres.
Jardiance 10 mg таблетки Емпаглифлозин
Jardiance 10 mg tablets Empagliflozin
Jardiance 10 mg филмирани таблетки Jardiance 25 mg филмирани таблетки
Jardiance 10 mg film-coated tablets Jardiance 25 mg film-coated tablets
Jardiance 10 mg филмирани таблетки Jardiance 25 mg филмирани таблетки емпаглифлозин (empagliflozin)
Jardiance 10 mg film-coated tablets Jardiance 25 mg film-coated tablets empagliflozin
Jardiance 10 mg филмирани таблетки Емпаглифлозин
Jardiance 10 mg film-coated tablets Empagliflozin
Jardiance 25 mg таблетки Емпаглифлозин
Jardiance 25 mg tablets Empagliflozin
Jardiance 25 mg филмирани таблетки Емпаглифлозин
Jardiance 25 mg film-coated tablets Empagliflozin
Jardiance в доза от 10 или 25 mg веднъж дневно е сравнен с плацебо (сляпо лечение), като се прилага самостоятелно или като допълнение към лечение с други противодиабетни лекарства (метформин, пиоглитазон или метформин плюс пиоглитазон или друг тип противодиабетно лекарство, наречено сулфонилурея).
Jardiance 10 or 25 mg once a day was compared with placebo (a dummy treatment) when used alone or added to treatment with other diabetes medicines (metformin, pioglitazone, or metformin plus either pioglitazone or another type of diabetes medicine called a sulfonylurea).
Jardiance е противодиабетно лекарство, което съдържа активното вещество емпаглифлозин (empagliflozin).
Jardiance is a diabetes medicine that contains the active substance empagliflozin.
Jardiance може да се използва без други лекарства при пациенти, които не могат да приемат метформин (друго лекарство за диабет).
Jardiance can be used without other medicines in patients who cannot take metformin (another diabetes medicine).
Jardiance може да се използва и с други лекарства.
Jardiance can also be used with other medicines.
Jardiance може да се използва самостоятелно при пациенти с диабет тип 2, при които не се постига задоволителен контрол на нивата на кръвната глюкоза с хранителен режим и упражнения и които не могат да приемат метформин (друго противодиабетно лекарство).
Jardiance can be used on its own in patients with type 2 diabetes whose blood glucose levels are not satisfactorily controlled on diet and exercise alone and who cannot take metformin (another diabetes medicine).
Jardiance може да се използва също като допълваща терапия към други противодиабетни лекарства, включително инсулин, когато тези лекарства заедно с упражнения и хранителен режим не осигуряват подходящ контрол на диабета.
Jardiance can also be used as an ‘add-on’ to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of the diabetes.
Javlor 25 mg/ml концентрат за инфузионен разтвор винфлунин (vinflunine)
Javlor 25 mg/mL concentrate for solution for infusion vinflunine
Javlor 25 mg/ml стерилен концентрат винфлунин
Javlor 25 mg/mL sterile concentrate vinflunine
Javlor e САМО за интравенозно приложение.
Javlor is for intravenous use ONLY.
Javlor e за еднократна употреба.
Javlor is for single use only.
Javlor инфузионен разтвор трябва да бъде подготвян и прилаган единствено от персонал, подходящо обучен за работа с цитотоксични средства.
Javlor solution for infusion should only be prepared and administered by personnel appropriately trained in the handling of cytotoxic agents.
Javlor инфузионен разтвор трябва да се включи в страничния инжекционен вход, най- близо до сака от 500 ml за по-нататъшно разреждане на Javlor по време на въвеждането.
The Javlor solution for infusion should be piggy-backed to the side injection port closest to the 500 mL bag to further dilute Javlor during administration.
Javlor инфузионен разтвор трябва да се включи в страничния инжекционен вход, най- близо до сака с 500 ml за по-нататъшно разреждане на Javlor по време на въвеждането.
The Javlor solution for infusion should be piggy-backed to the side injection port closest to the 500 mL bag to further dilute Javlor during administration.
Javlor инфузионен разтвор трябва да се приложи като инфузия в продължение на 20 минути.
The Javlor solution for infusion should be infused over 20 minutes.
Javlor инфузионен разтвор трябва да се се инфузира в продължение на 20 минути.
The Javlor solution for infusion should be infused over 20 minutes.
Javlor трябва да се разреди преди употреба.
Javlor must be diluted prior to administration.
Je bel do bodisi svetlo rumen bodisi zeleno-rumen liofiliziran prašek.
It is a white to either light yellow or green-yellow lyophilised powder.
Je běžné, že se používá v kombinaci s jinými anti-HIV léky, které pomáhají kontrolovat infekci HIV.
It is normally used in combination with other anti-HIV medicines to help control your HIV infection.
Je důležité, abyste nevynechal(a) žádnou dávku přípravku EVOTAZ ani jiného léku proti HIV.
It is important that you do not miss any doses of EVOTAZ or your other anti-HIV medicines.
Je klinicky dokázáno, že alli Vám pomůže snížit hmotnost více než samotná dieta.
alli is clinically proven to help you lose more weight than dieting alone.
Je možné, že bude třeba léčbu ukončit.
It may be necessary to discontinue treatment.
Je možné, že bude třeba užívání alli ukončit.
You may need to stop taking alli.
Je možné, že bude třeba, abyste přestali alli užívat.
You may need to stop taking alli.
Je možné, že během léčby alli bude třeba upravit dávkování amiodaronu.
The dose of amiodarone may need to be adjusted during treatment with alli.
Je možné, že systémové vstřebávání z 27 mg žvýkacích tablet je vyšší než vstřebávání z 60 mg tvrdých tobolek.
It is possible that the systemic absorption from 27 mg chewable tablets may be higher than that from 60 mg hard capsules.
Je možné, že Váš lékař bude chtít přehodnotit léčbu.
Your doctor may want to review your treatment.
Je nepravděpodobné, že by alli ovlivnilo Vaši schopnost řídit dopravní prostředek nebo obsluhovat stroje nebyl pozorován.
alli is unlikely to affect your ability to drive and use machines.
Je nepravděpodobné, že by alli ovlivnilo Vaši schopnost řídit dopravní prostředky nebo obsluhovat stroje.
alli is unlikely to affect your ability to drive and use machines.
Je nutno dodržovat opatření k zabránění přenosu v souladu s národními doporučeními.
Precautions to prevent transmission should be taken in accordance with national guidelines.
Je potrebné použiť príslušné aseptické postupy.
Appropriate aseptic techniques must be used.
Je třeba opatrnosti.
Caution is warranted.
Je třeba opatrnosti.
Caution should be exercised.
JE VAX N=370
JE-VAX N=370
JE VAX N=370 GMT (n)
JE-VAX N=370 GMT (n)
Je zde riziko ztráty léčebného efektu a vzniku rezistence na atazanavir (viz bod 4.3).
There is a risk of loss of therapeutic effect and development of resistance to atazanavir (see section 4.3).
Jeden ml pripraveného roztoku obsahuje 0,05 mg trabektedínu.
One ml of reconstituted solution contains 0.05 mg of trabectedin.
Jedna 1mg tableta obsahuje 22,41 mg laktosy (ve formě monohydrátu).
Each 1 mg tablet contains 22.41 mg of lactose (as monohydrate).
Jedna 2mg tableta obsahuje 44,82 mg laktosy (ve formě monohydrátu).
Each 2 mg tablet contains 44.82 mg of lactose (as monohydrate).
Jedna 3mg tableta obsahuje 37,81 mg laktosy (ve formě monohydrátu).
Each 3 mg tablet contains 37.81 mg of lactose (as monohydrate).
Jedna 4mg tableta obsahuje 50,42 mg laktosy (ve formě monohydrátu).
Each 4 mg tablet contains 50.42 mg of lactose (as monohydrate).
Jedna injekčná liekovka obsahujúca 0,25 mg trabektedínu sa rozpustí v 5 ml sterilnej vody na injekciu.
Each vial containing 0.25 mg of trabectedin is reconstituted with 5 ml of water for injections.
Jedna injekčná liekovka obsahujúca 1 mg trabektedínu sa rozpustí v 20 ml sterilnej vody na injekciu.
Each vial containing 1 mg of trabectedin is reconstituted with 20 ml of water for injections.
Jedna injekčná liekovka prášku obsahuje 0,25 mg trabektedínu.
Each vial of powder contains 0.25 mg of trabectedin.
Jedna injekčná liekovka prášku obsahuje 2 mg draslíka a 0,1 g sacharózy.
Each vial of powder contains 2 mg of potassium and 0.1 g of sucrose.
Jedna injekčná liekovka prášku obsahuje 8 mg draslíka a 0,4 g sacharózy.
Each vial of powder contains 8 mg of potassium and 0.4 g of sucrose.
Jedna potahovaná tableta obsahuje atazanavirum 300 mg (jako atazanaviri sulfas) a cobicistatum 150 mg.
Each film-coated tablet contains 300 mg of atazanavir (as sulphate) and 150 mg of cobicistat.
Jedna potahovaná tableta obsahuje atazanavirum 300 mg (jako atazanaviri sulfas) a cobicistatum 150 mg.
Each film-coated tablet contains atazanavir sulphate corresponding to 300 mg atazanavir and 150 mg of cobicistat.
Jedna potahovaná tableta obsahuje atazanavirum 300 mg (jako atazanavirum sulfas) a cobicistatum 150 mg.
Each film-coated tablet contains 300 mg of atazanavir (as sulphate), and 150 mg cobicistat.
Jedna tableta obsahuje 300 mg klopidogrelu (ve formě hydrogensulfátu)
Each tablet contains 300 mg of clopidogrel (as hydrogen sulphate).
Jedna tableta obsahuje 75 mg klopidogrelu (ve formě hydrogensulfátu)
Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate).
Jedna tableta přípravku EVOTAZ je bioekvivalentní jedné tobolce atazanaviru (300 mg) spolu s jednou tabletou kobicistatu (150 mg) po jednorázové perorální dávce podané zdravým jedincům spolu s lehkým jídlem (n=62).
One EVOTAZ tablet is bioequivalent to one atazanavir capsule (300 mg) plus one cobicistat tablet (150 mg) following single oral dose administration with a light meal in healthy subjects (n=62).
Jedna tobolka obsahuje 60 mg orlistatum.
Each hard capsule contains 60 mg orlistat.
Jedna tvrdá tobolka obsahuje 60 mg orlistatum.
Each hard capsule contains 60 mg of orlistat.
Jedna tvrdá tobolka obsahuje 60 mg orlistatum.
Each hard capsule contains 60 mg orlistat.
Jedna žvýkací tableta obsahuje 27 mg orlistatum.
Each chewable tablet contains 27 mg of orlistat.
Jedna žvýkací tableta obsahuje 27 mg orlistatum.
Each chewable tablet contains 27 mg orlistat.
Jedna žvýkací tableta obsahuje 86,79 mg laktosy (bezvodé) a 6,48 mg sacharosy (jako monopalmitát).
Each chewable tablet contains 86.79 mg of lactose (as anhydrous) and 6.48 mg of sucrose (as monopalmitate).
jednorázová dávka (atazanavir
(atazanavir 400 mg once daily)
jednou denně odpoledne, 12 hodin
12 hours after omeprazole)
jednou denně s ritonavirem 100 mg
ritonavir 100 mg once daily pm,
Jedná se například o cytomegalovirovou retinitidu, generalizované a/nebo fokální mykobakteriální infekce a pneumonii způsobenou Pneumocystis jiroveci.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia.
Jejich frekvence není známa (viz bod 4.4).
The frequency of this is unknown (see section 4.4).
Jeklenke INOmax je treba shranjevati varno, tako da ne morejo pasti in povzročiti škode.
INOmax cylinders should be stored secured in order to avoid falling and thus potentially causing harm.
jeklenke morajo biti pritrjene, da preprečite padce
the gas cylinders should be fixedly stowed away in order to avoid untimely fall
Jeklenke morate prevažati z ustrezno opremo, da bi jih zaščitili pred nevarnostjo padcev in udarcev.
The gas cylinders should be transported with appropriate material in order to protect them from risks of shocks and falls.